|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 2 | Personalising pancreas cancer treatment:When tissue is the issue显示文摘The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice. | Katrin M Sjoquist Venessa T Chin Lorraine A Chantrill Chelsie O'Connor Chris Hemmings David K Chang Angela Chou Marina Pajic Amber L Johns Adnan M Nagrial Andrew V Biankin Desmond Yip | 2014 | World Journal of Gastroenterology2014，20，24： | 2 |
| 3 | Insulin- leptin - visceral fat relation during weight loss显示文摘 | Yip I Go V L Hershman J M | 2001 | Pancreas2001，23，： | 1 |
| 4 | Early ap- praisal of China's huge and complex health-care re- forms显示文摘 | Yip W C M Hsiao W C ChenW | 2012 | Lancet2012，379，9818： | 1 |
| 5 | Estimated cost savings of in- creased use of intravenous tissue plasminogen activator for a- cute ischemic stroke in Canada 显示文摘 | Yip T R Demaerschalk B M | 2007 | Stroke2007，38，6： | 1 |
| 6 | The Hang Kong Diastolic Heart Failure Study : a randomized control trial of diuretics, irbesartan and ramipril on quality of life,exercise capacity,left ventricular global and regional function in heart failure with a normal ejection fraction 显示文摘 | Yip GW Wang M Wang T | 2008 | Heart2008，94，5： | 1 |
| 7 | Clinical applications of strain rate imaging显示文摘 | Yip G Abraham T Belohlavek M | 2003 | J Am Soc Echocardiogr2003，16，12： | 1 |
| 8 | The Obligatory Contour Principle and phonological rules: A loss of identity显示文摘 | Yip M | 1988 | Linguistic Inquiry1988，，19： | 1 |
| 9 | Psychosocial adjustment in gynecologic cancer survivors:A longitudinal study on risk factors for maladjustment显示文摘 | Chan Y M Ngan H Y S Yip P S F | 2001 | Gynecol Oncol2001，80，3： | 1 |
| 10 | Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value显示文摘 | Wang M Yip GW Wang AY | 2003 | J Am Coll Cardiol2003，41，5： | 1 |
| 11 | Stroke in young women显示文摘 | Salisbury M Pfeffer G Yip S | 2011 | Can J Neurol Sci2011，38，3： | 1 |
| 12 | A review on projected clus- tering algorithms显示文摘 | Yip K Y Ng M K Cheung D W | 2003 | International Journal of Applied Math- ematics2003，13，1： | 1 |
| 13 | Open-ended TiO nanotubes formed by two-step anodization and their application in dye-sensitized solar cells 显示文摘 | Yip C T Guo M Huang H | 2012 | Nanoscale2012，4，2： | 1 |
| 14 | Cantonese loanword phonology and optimality theory显示文摘 | Yip M | 1993 | Journal of East Asian Linguistics1993，，2： | 1 |
| 15 | Phonological Constraints, Optimality and Phonetic Real- ization in Cantonese 显示文摘 | Yip M | 1996 | UCI Working Papers in Linguistics1996，，： | 1 |
| 16 | Expression of the regeneration-associated protein SPRR1A in primary sensory neurons and spinal cord of the adult mouse following peripheral and central injury显示文摘 | Starkey ML Davies M Yip PK | | 0，，01： | 1 |
| 17 | Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical pa- tients显示文摘 | Sobieraj-Teague M Hirsh J Yip G | 2012 | J Thromb Haemost2012，10，2： | 1 |
| 18 | Proteomic analyses of arsenic- induced cell transformation with SELDI-TOF ProteinChip technology显示文摘 | He QY Yip TT Li M | 2003 | J Cell Biochem2003，88，1： | 1 |
| 19 | Ruthenium-catalyzed oxidation of alkenes, alkynes, and alcohols to organic acids with aqueous hydrogen peroxide显示文摘 | Che C M Yip W P Yu W Y | 2006 | Chemistry--An Asian Journal2006，1，45： | 1 |
| 20 | Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates 显示文摘 | Frost D Gorman P M Yip C M | 2003 | Eur J Biochem2003，270，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员